ARA-290
Men's HealthMale-physiology practitioners evaluate ARA-290 against the HPG axis, androgenic markers, and downstream effects on body composition, libido, and recovery. Selectively activates the innate repair receptor (β-common-receptor / EPOR heteromer) on injured tissue Reduces inflammatory cytokine release and supports nerve and tissue repair. Critically, it does not bind the homodimeric EPOR responsible for erythropoiesis.. For men running ARA-290 alongside TRT, post-cycle restarts, or fertility-aware protocols, baseline labs (total/free testosterone, LH, FSH, estradiol, prolactin, SHBG) and a 6-8 week follow-up panel are the standard monitoring framework at the 4 mg 1x daily subq dose.
Key Takeaways
Male-physiology lens: ARA-290 is evaluated against HPG-axis interaction, TRT compatibility, and prostate / cardiovascular considerations. Mechanism: Selectively activates the innate repair receptor (β-common-receptor / EPOR heteromer) on injured tissue. Male monitoring: baseline testosterone (total/free), LH, FSH, estradiol, prolactin, SHBG; 6-8 week follow-up panel. Male dose: 4 mg 1x daily subq via subq; cycle 8-12 weeks. Male-physiology stack partners: Kisspeptin, Gonadorelin (GnRH), PT-141.
Selectively activates the innate repair receptor (β-common-receptor / EPOR heteromer) on injured tissue. Reduces inflammatory cytokine release and supports nerve and tissue repair. Critically, it does not bind the homodimeric EPOR responsible for erythropoiesis. The male-physiology question is how this mechanism interacts with the HPG axis, with exogenous testosterone or HCG-paired protocols, and with prostate, hematocrit, and cardiovascular indices. The subsections below address HPG-axis interaction, TRT compatibility, body composition response, and prostate considerations for ARA-290.
Compatibility with TRT and post-cycle protocols
For men currently on TRT or planning a post-cycle restart, ARA-290 is typically compatible because it does not directly engage the HPG axis. The dominant interaction to watch for is on the metabolic and recovery layers rather than the hormonal layer. Where the molecule's pharmacology overlaps with HCG, gonadorelin, or kisspeptin, dose layering is the standard approach.
Sexual function and prostate considerations
Where ARA-290 alters circulating LH, testosterone, or local androgen signalling, prostate considerations become relevant for men over 40. Baseline PSA, periodic re-check, and avoidance of stacking that compounds androgenic load are all reasonable precautions. For molecules whose effects are predominantly outside the HPG axis, the prostate consideration is largely background.
Interaction with the HPG axis
ARA-290's relationship to the male HPG axis is one of the central practical questions. Direct receptor-level engagement of the HPG axis is not the principal mechanism, but downstream effects on testosterone, LH/FSH, and prolactin can still occur and warrant baseline and follow-up labs in male users. The practical takeaway is that any male user beginning a course of ARA-290 should have a baseline hormone panel and a follow-up at 6–8 weeks to detect drift.
For erectile function in male users, ARA-290 is most-effective when paired with comprehensive labs (testosterone total/free, LH, FSH, estradiol sensitive, prolactin, SHBG) at baseline and follow-up. Cycle length 8–12 weeks with re-evaluation.
Sleep Quality in men responds to ARA-290 with effect sizes that vary substantially by baseline status — men with documented suboptimal status respond more strongly than those at the upper end of normal. The protocol pattern in clinical use reflects this.
Where male users target andropause, ARA-290 is typically integrated with the broader hormonal protocol — TRT, kisspeptin, gonadorelin, or HCG — rather than used in isolation. The integration approach varies by clinic.
For cardiovascular health (male) in male users, ARA-290 is most-effective when paired with comprehensive labs (testosterone total/free, LH, FSH, estradiol sensitive, prolactin, SHBG) at baseline and follow-up. Cycle length 8–12 weeks with re-evaluation.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | 4 mg | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | 2 mg | 4–6 weeks initial cycle |
| Men's Health focus | SubQ | 4 mg | 1x daily SubQ |
| Maintenance phase | SubQ | 3 mg | Ongoing with periodic pauses |
Dose timing for ARA-290 is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.
ARA-290 stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from men's-health clinicians.
- ARA-290 + Kisspeptin: Activates the KISS1R (GPR54) on GnRH neurons in the hypothalamus, triggering GnRH release. Pairs naturally with ARA-290's mechanism in male physiology protocols.
- ARA-290 + Gonadorelin (GnRH): Binds the GnRH receptor on anterior pituitary gonadotrophs in a pulsatile fashion to stimulate LH (and to a lesser extent FSH) release. Pairs naturally with ARA-290's mechanism in male physiology protocols.
- ARA-290 + PT-141: Activates MC4R in the hypothalamus and other CNS regions involved in sexual response. Pairs naturally with ARA-290's mechanism in male physiology protocols.
- ARA-290 + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with ARA-290's mechanism in male physiology protocols.
Excellent tolerability in published trials. Does not raise hemoglobin. Watch for rare injection site reactions.
Lens-specific safety considerations for male physiology use of ARA-290: Excellent tolerability in published trials. Does not raise hemoglobin. Watch for rare injection site reactions. Additional male physiology monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| ARA-290 | EPO-derived tissue-protective peptide | ~2 min plasma; long tissue effect | Men's Health |
| Kisspeptin | Hypothalamic upstream regulator of GnRH | ~28 min IV | The upstream master regulator of GnRH neurons — driving the entire HPG axis from above |
| Gonadorelin (GnRH) | Hypothalamic decapeptide | ~2-4 min | The natural decapeptide that drives pituitary release of LH and FSH — used clinically and increasingly as an HCG alternative during testosterone therapy |
| PT-141 | Melanocortin receptor agonist | ~2-3 hr | An MC3R/MC4R agonist derived from Melanotan II — FDA-approved as bremelanotide for HSDD in premenopausal women |
How does ARA-290 affect the HPG axis?
Will ARA-290 affect fertility or sperm quality?
Does ARA-290 affect hair, prostate, or erythrocyte production?
What blood work should I run on this protocol?
What is ARA-290?
How does ARA-290's half-life affect dosing?
Start a ARA-290 Protocol
Alukard provides physician-supervised men's health protocols with GMP-certified ARA-290 and GMP-certified compounds with comprehensive hormone panels.
Get ProtocolQuick Facts
- Molecular weight
- 1257 Da
- Sequence length
- 11 aa
- Half-life
- ~2 min plasma; long tissue effect
- WADA
- Not specifically listed (EPO analogues require care)
- FDA
- Unapproved (Phase II/III in sarcoidosis & neuropathy)
- Research
- Multiple Phase II human trials
All male physiology applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for ARA-290 unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Male Physiology Protocol for ARA-290
Alukard provides physician-supervised men's health protocols with GMP-certified compounds with comprehensive hormone panels.
HIPAA Compliant · GMP Certified · Physician Supervised